Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plozalizumab

Next Previous
X
Search
Drug Profile

Plozalizumab

Alternative Names: Anti-CCR2 monoclonal antibody; MLN-1202; TAK-202

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Millennium; Millennium Pharmaceuticals; Takeda; Takeda Oncology
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atherosclerosis; Diabetic nephropathies
  • No development reported Malignant melanoma
  • Discontinued Multiple sclerosis; Rheumatoid arthritis; Scleroderma; Solid tumours

Most Recent Events

  • 28 Jun 2019 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (IV, Infusion)
  • 09 May 2018 Millennium Pharmaceuticals terminates a phase I trial in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA, due to business decision (IV) (NCT02723006)
  • 28 Jul 2017 Phase-I clinical trials in Solid tumours in USA (Parenteral) (3285061; Takeda Q2 report,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top